Global Prostate Cancer Diagnostics Market Trends & Summary

The global prostate cancer diagnostics market is entering a transformative decade—one shaped by technological breakthroughs, rising patient awareness, and a rapidly expanding elderly population. According to Renub Research, the market is projected to surge from US$ 4.68 billion in 2024 to US$ 13.36 billion by 2033, registering an impressive CAGR of 12.35% from 2025 to 2033. This sustained momentum reflects accelerating adoption of early detection programs, novel biomarkers, precision imaging tools, and AI-driven diagnostics across both developed and emerging economies.

As prostate cancer continues to rank among the most common cancers in men worldwide, the demand for reliable, accessible, and cost-efficient diagnostic solutions has never been higher. Governments, clinicians, and research institutions are now actively collaborating to reduce disparities in screening access and expand the availability of advanced tools capable of identifying cancer early—when treatment outcomes are most favorable.

Download Free Sample Report

Prostate Cancer Diagnostics Market Overview

Prostate cancer diagnostics encompass a suite of clinical evaluations, imaging modalities, laboratory assays, and biopsy techniques designed to detect cancerous changes in the prostate gland. Traditionally, the diagnostic pathway has relied on:

PSA (Prostate-Specific Antigen) blood test

Digital Rectal Examination (DRE)

Tissue biopsy

However, modern diagnostics increasingly incorporate advanced imaging technologies such as:

Multiparametric MRI (mpMRI)

PET/CT & PSMA-PET imaging

High-resolution transrectal ultrasound

Emerging tools—ranging from liquid biopsies to genomic assays—are redefining accuracy, making early diagnosis more achievable than ever. The objective is clear: to identify malignancies at their earliest stages, stratify risk with precision, and guide clinicians towards the most personalized treatment pathway.

As prostate cancer becomes more prevalent in aging populations worldwide, the need for accurate diagnostics continues to deepen. Early detection directly influences survival rates and reduces the burden of overtreatment by differentiating between aggressive and non-aggressive tumors.

Key Growth Drivers of the Prostate Cancer Diagnostics Market

1. Rising Global Incidence of Prostate Cancer

The global rise in prostate cancer cases—driven largely by increased life expectancy, lifestyle patterns, and greater screening awareness—is fueling strong demand for diagnostic tools. Prostate cancer ranks as:

The 2nd most common cancer in men worldwide

The 5th leading cause of cancer-related deaths globally

In September 2024 data, about 1 in 5 individuals is expected to develop cancer in their lifetime. Notably, more men than women succumb to cancer (1 in 9 men vs. 1 in 12 women).

Prostate cancer is the most frequently diagnosed cancer in men in 118 of 185 countries, reflecting stark geographical disparities in awareness, screening, and access to timely treatment. Higher diagnostic uptake corresponds strongly with improved survival outcomes, underscoring the importance of widespread screening programs.

2. Technological Advances in Diagnostic Imaging & Molecular Testing

Next-generation diagnostic technologies are revolutionizing prostate cancer detection. These include:

Multiparametric MRI (mpMRI) for precise tumor localization

PET scans and PSMA-targeted imaging for improved staging

Genetic and molecular biomarker assays

AI-driven pathology tools

AI is playing a pivotal role in accelerating accuracy and minimizing false positives. In December 2024, the University of Texas Medical Branch became the first academic health center in Texas to integrate AI-based prostate biopsy overlays from Ibex, enhancing pathologists’ ability to interpret tissue samples.

These innovations are helping clinicians tailor treatment plans while improving screening sensitivity and specificity.

3. Government Initiatives & Public Awareness Campaigns

Governments worldwide are prioritizing early prostate cancer detection through:

Public health campaigns

Reimbursement expansions

Funding for diagnostic R&D

National screening programs

While colorectal cancer has been the focus of several major campaigns, the model—such as the CDC's Screen for Life program—serves as a blueprint for similar efforts in prostate cancer screening. Increased funding and targeted communication efforts are driving more men to seek early examinations, significantly boosting diagnostic volumes.

Challenges in the Prostate Cancer Diagnostics Market

1. High Cost of Advanced Diagnostic Technologies

Sophisticated modalities like MRI, PET scans, and molecular imaging require:

High capital investments

Highly trained staff

Advanced healthcare infrastructure

In low- and middle-income nations, these costs limit accessibility, delaying diagnosis and negatively impacting patient outcomes. Even in wealthier countries, reimbursement gaps pose barriers to widespread adoption.

2. Limited Access in Rural & Remote Areas

Rural populations often face:

Shortage of trained urologists and radiologists

Limited imaging equipment availability

Lack of diagnostic centers capable of performing biopsies

As a result, men in rural regions are frequently diagnosed at later stages, directly affecting survivability. Bridging this divide will require mobile diagnostics, telemedicine expansion, and government-driven infrastructure improvements.

Market by Type

Benign Prostatic Hyperplasia (BPH) Diagnostics

BPH diagnostics involve:

DRE

Urinalysis

PSA tests

Ultrasound imaging

With aging populations swelling globally, BPH cases are increasing rapidly. Early detection is crucial to avoid complications such as urinary retention. Technological improvements continue to refine diagnostic differentiation between BPH and malignancy.

Prostatic Adenocarcinoma Diagnostics

Prostatic adenocarcinoma accounts for the majority of prostate cancer diagnoses. Diagnostics include:

PSA screening

Biopsies

mpMRI

Molecular tests

PET imaging

Advances in precision medicine—particularly genomic profiling and liquid biopsy—are improving treatment customization and boosting this segment's growth.

Small Cell Carcinoma & Other Rare Types

Though less common, rare prostate cancer subtypes require advanced diagnostic tools and pathological evaluations. Growing awareness and research into these variants contribute moderately to market expansion.

Market by Test Type

1. Preliminary Tests

Including PSA and DRE, these tests serve as the frontline screening tools worldwide. Despite PSA’s limitations, it remains the most widely used method for detecting prostate abnormalities. Increased adoption of routine screening is driving strong demand across this segment.

2. Confirmatory Tests

Confirmatory diagnostics include:

Biopsies

MRI and PET imaging

Genomic assays

The shift toward minimally invasive and highly accurate confirmatory tests—such as fusion-guided biopsies—has strengthened this market segment.

Market by End User

Hospitals

Hospitals dominate the diagnostics landscape due to their access to:

High-end imaging equipment

Skilled clinicians

Comprehensive care pathways

As prostate cancer incidence grows, hospitals increasingly integrate mpMRI, genetic testing, and AI-assisted pathology into workflows.

Diagnostic Centers

Standalone centers provide cost-effective alternatives for PSA testing, imaging, and biopsies. Their expansion in urban and semi-urban locations is boosting market demand.

Research Institutes

Research institutes are accelerating innovation by:

Developing biomarkers

Conducting clinical trials

Advancing genetic profiling

Innovating liquid biopsy technologies

Their collaborations with industry players drive commercialization of next-generation tools.

Others

This category includes private clinics, mobile diagnostic units, and government-funded screening facilities.

Country-Level Market Highlights

Canada

Prostate cancer is the most diagnosed cancer in Canadian men, with strong diagnostic uptake. Canada's universal healthcare system supports early screening initiatives, significantly boosting PSA and imaging volumes. In January 2025, Ontario became the first province to publicly fund PLUVICTO™, a breakthrough treatment for late-stage prostate cancer—reflecting broader commitment to cancer care innovation.

Germany

Germany continues to lead in Europe with:

High adoption of mpMRI

Strong R&D culture

Advanced PSMA-PET/CT imaging

A 2023 study at the University Hospital Bonn showcased the effectiveness of PSMA-PET/CT for more precise biopsy targeting, helping detect clinically significant prostate cancer earlier.

China

China's diagnostic market is expanding rapidly due to rising awareness and extensive healthcare modernization. With government-backed cancer prevention programs and regulatory approvals—such as the July 2024 NMPA approval of XTANDI®—China is strengthening both diagnostic and treatment landscapes.

United Arab Emirates

The UAE’s robust healthcare investments are elevating prostate cancer detection rates. In January 2025, MOHAP approved the Fortel® PSA Home Screening Test, enabling early, at-home assessments—an important step toward improving early detection among Middle Eastern men.

Market Segmentation Summary

By Type (4 viewpoints):

Benign Prostatic Hyperplasia

Prostatic Adenocarcinoma

Small Cell Carcinoma

Others

By Test Type (2 viewpoints):

Preliminary Tests

Confirmatory Tests

By End User (4 viewpoints):

Hospitals

Diagnostic Centers

Research Institutes

Others

By Country (25 viewpoints):

North America, Europe, Asia-Pacific, Latin America, Middle East & Africa — covering 25 individual markets including the U.S., China, Germany, India, Japan, UAE, Brazil, and more.

Company Analysis (10 Major Players)

F. Hoffman-La Roche AG

Bayer AG

Thermo Fisher Scientific Inc.

Abbott Laboratories Inc.

Siemens Healthineers AG

Becton Dickinson and Company

Agilent Technologies Inc.

Hologic Inc.

Qiagen N.V.

OPKO Health Inc.

Each company is assessed across:

Overview | Recent Developments | Product Portfolio | Revenue

Final Thoughts

The global prostate cancer diagnostics market stands at a pivotal moment. With early detection emerging as the cornerstone of effective cancer management, the integration of AI-powered tools, advanced imaging, and liquid biopsies is reshaping clinical pathways across the world. Rising awareness, government initiatives, and demographic shifts will continue to expand market demand throughout the coming decade.

As Renub Research forecasts a leap to US$ 13.36 billion by 2033, the pace of innovation suggests that diagnostic accuracy, accessibility, and personalization will advance more in the next ten years than in the previous three decades combined. The market’s evolution will play a decisive role in reducing mortality, improving quality of life, and ensuring that more men receive timely, life-saving care.